

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	29	JUN 25	CA/CAPLUS and USPAT databases updated with IPC reclassification data

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 07:50:51 ON 26 JUN 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.63	0.63

FILE 'REGISTRY' ENTERED AT 07:52:38 ON 26 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 25 JUN 2008 HIGHEST RN 1030702-50-1
DICTIONARY FILE UPDATES: 25 JUN 2008 HIGHEST RN 1030702-50-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:


<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s solifenacin/cn
L1 1 SOLIFENACIN/CN

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 242478-37-1 REGISTRY
ED Entered STN: 29 Sep 1999
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)
OTHER NAMES:
CN Solifenacin
CN YM 905
FS STEREOSEARCH
MF C23 H26 N2 O2
CI COM
SR US Adopted Names Council (USAN)
LC STN Files: ADISINSIGHT, ANABSTR, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS,
IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, PATDPASPC, PHAR,
PS, TOXCENTER, USAN, USPAT2, USPATFULL

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

87 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
88 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s l1 full
L2 1 SOLIFENACIN/CN

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	12.76	13.39

FILE 'CAPLUS' ENTERED AT 07:53:25 ON 26 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 26 Jun 2008 VOL 148 ISS 26
FILE LAST UPDATED: 25 Jun 2008 (20080625/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l2 full
L3 88 L2

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.92	15.31

FILE 'USPATFULL' ENTERED AT 07:56:02 ON 26 JUN 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 24 Jun 2008 (20080624/PD)
FILE LAST UPDATED: 24 Jun 2008 (20080624/ED)
HIGHEST GRANTED PATENT NUMBER: US7392547
HIGHEST APPLICATION PUBLICATION NUMBER: US20080148460
CA INDEXING IS CURRENT THROUGH 24 Jun 2008 (20080624/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 24 Jun 2008 (20080624/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2008
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Apr 2008

USPATFULL now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

=> s l3 full
L4 45 L2

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2008:167948 USPATFULL
TITLE: NOVEL COMPOUNDS
INVENTOR(S): Bamborough, Paul, Stevenage, UNITED KINGDOM
Barker, Michael David, Stevenage, UNITED KINGDOM
Campos, Sebastien Andre, Stevenage, UNITED KINGDOM
Cousins, Richard Peter Charles, Stevenage, UNITED KINGDOM
Faulder, Paul, Stevenage, UNITED KINGDOM
Hobbs, Heather, Stevenage, UNITED KINGDOM
Holmes, Duncan Stuart, Stevenage, UNITED KINGDOM
Johnston, Michael John, Stevenage, UNITED KINGDOM
Liddle, John, Stevenage, UNITED KINGDOM
Payne, Jeremy John, Stevenage, UNITED KINGDOM
Pritchard, John Martin, Stevenage, UNITED KINGDOM
Whitworth, Caroline, Stevenage, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080146606	A1	20080619
APPLICATION INFO.:	US 2007-858143	A1	20070920 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2006-18776	20060922
	GB 2007-4012	20070301
	GB 2007-17170	20070904
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SMITHKLINE BEECHAM CORPORATION, CORPORATE INTELLECTUAL PROPERTY-US, UW2220, P. O. BOX 1539, KING OF PRUSSIA, PA, 19406-0939, US	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	7746	

AB The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I):

##STR1##

and salts thereof.

The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.

L4 ANSWER 2 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2008:152229 USPATFULL

TITLE: Purine Derivative

INVENTOR(S): Blatcher, Philip, Hertfordshire, UNITED KINGDOM
Cousins, Richard Peter Charles, Hertfordshire, UNITED KINGDOM

PATENT ASSIGNEE(S): Evans, Derek Norman, Hertfordshire, UNITED KINGDOM
GLAXO GROUP LIMITED, Greenford, UNITED KINGDOM
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080132526	A1	20080605
APPLICATION INFO.:	US 2005-569406	A1	20050523 (11)
	WO 2005-EP5651		20050523
			20061120 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2004-11563	20040524
	GB 2005-9521	20050510
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1-8	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1456	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a compound of formula (I) and salts and solvates thereof. Compounds of formula (I) are agonists of the adenosine A2.sub.A receptor and are believed to be of potential use in the treatment of inflammatory diseases such as asthma and chronic obstructive pulmonary disease.

##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2008:131203 USPATFULL
TITLE: Solifenacin base forms and preparation thereof
INVENTOR(S): Koltai, Tamas, Netanya, ISRAEL
Perlman, Nurit, Kfar Saba, ISRAEL
Nidam, Tamar, Yehud, ISRAEL
Abramov, Mili, Givataim, ISRAEL

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080114171	A1	20080515
APPLICATION INFO.:	US 2007-890316	A1	20070803 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-835806P	20060803 (60)
	US 2006-845260P	20060918 (60)
	US 2006-845261P	20060918 (60)
	US 2006-859951P	20061120 (60)
	US 2006-859952P	20061120 (60)
	US 2007-878913P	20070104 (60)
	US 2007-898789P	20070131 (60)
	US 2007-898888P	20070131 (60)
	US 2007-930391P	20070515 (60)
	US 2007-949112P	20070711 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KENYON & KENYON LLP, ONE BROADWAY, NEW YORK, NY, 10004,
US
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 650


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polymorphic forms of solifenacin base have been prepared and characterized. These polymorphic forms are particularly useful for preparing solifenacin salts.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 242478-37-1P, Solifenacin
(solifenacin base forms and preparation thereof)
RN 242478-37-1 USPATFULL
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 4 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2008:131061 USPATFULL
TITLE: Polymorphs of solifenacin intermediate
INVENTOR(S): Koltai, Tamas, Netanya, ISRAEL
Perlman, Nurit, Kfar Saba, ISRAEL
Nidam, Tamar, Yehud, ISRAEL
Diller, Dov, Jerusalem, ISRAEL

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080114029	A1	20080515
APPLICATION INFO.:	US 2007-890264	A1	20070803 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-835806P	20060803 (60)
	US 2006-845260P	20060918 (60)
	US 2006-845261P	20060918 (60)
	US 2006-859951P	20061120 (60)
	US 2006-859952P	20061120 (60)
	US 2007-878913P	20070104 (60)
	US 2007-898789P	20070131 (60)
	US 2007-898888P	20070131 (60)
	US 2007-930391P	20070515 (60)
	US 2007-949112P	20070711 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KENYON & KENYON LLP, ONE BROADWAY, NEW YORK, NY, 10004,
US
NUMBER OF CLAIMS: 28
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 310


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polymorphic forms of 1(S)-phenyl-1,2,3,4-tetrahydroisoquinoline have been prepared and characterized. These polymorphic forms are particularly useful for preparing solifenacin salts.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 242478-37-1P, Solifenacin
(solifenacin base forms and preparation thereof)
RN 242478-37-1 USPATFULL
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 5 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2008:131060 USPATFULL

TITLE: Process for preparing polymorphic forms of solifenacin succinate

INVENTOR(S): Koltai, Tamas, Netanya, ISRAEL
Nidam, Tamar, Yehud, ISRAEL
Gilboa, Eyal, Bat-Yam, ISRAEL
Perlman, Nurit, Kfar Saba, ISRAEL
Pinhasov, Michael, Dover, NJ, UNITED STATES
Abramov, Mili, Givataim, ISRAEL

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080114028	A1	20080515
APPLICATION INFO.:	US 2007-881161	A1	20070724 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-833542P	20060724 (60)
	US 2006-846192P	20060920 (60)
	US 2006-861420P	20061129 (60)
	US 2007-924787P	20070531 (60)
	US 2007-924902P	20070605 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: KENYON & KENYON LLP, ONE BROADWAY, NEW YORK, NY, 10004, US

NUMBER OF CLAIMS: 123

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 4 Drawing Page(s)

LINE COUNT: 1718

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Polymorphic forms of solifenacin have been prepared and characterized.
These polymorphic forms are particularly useful in pharmaceutical compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 242478-37-1P, Solifenacin

(preparation of polymorphic forms of solifenacin succinate for dosage forms for treating overactive bladder)

RN 242478-37-1 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 6 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2008:118473 USPATFULL
TITLE: Stable Particular Pharmaceutical Composition of
Solifenacin or Salt Thereof
INVENTOR(S): Umejima, Hiroyuki, Tokyo, JAPAN
Ohi, Hiroshi, Tokyo, JAPAN
Saito, Katsumi, Tokyo, JAPAN
Taketani, Yuko, Tokyo, JAPAN
PATENT ASSIGNEE(S): ASTELLAS PHARMA INC., Tokyo, JAPAN (non-U.S.
corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20080103171	A1	20080501	
APPLICATION INFO.:	US 2005-721863	A1	20051226	(11)
	WO 2005-JP23771		20051226	
			20070615	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2005-85968	20050324
	US 2004-638388P	20041227 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SUGHRUE-265550, 2100 PENNSYLVANIA AVE. NW, WASHINGTON, DC, 20037-3213, US	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	1372	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to the provision of a stable particulate pharmaceutical composition of solifenacin or a salt thereof, which is in a spherical shape suitable for coating and in which degradation with time can be inhibited when a pharmaceutical preparation of solifenacin or a salt thereof is supplied to clinical fields. More particularly, it relates to a particulate pharmaceutical composition that can be obtained by using a binder having a Tg or mp lower than 174C upon formulating a particulate composition of solifenacin into a pharmaceutical preparation. Further, by performing a crystallization-promoting treatment after the particulate pharmaceutical composition is produced, a more stable particulate composition of solifenacin or a salt thereof can be provided.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 242478-37-1, Solifenacin
(solid pharmaceutical compns. containing crystalline solifenacin having improved stability, and manufacture thereof)

RN 242478-37-1 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 7 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2008:104547 USPATFULL

TITLE: Processes for optical resolution of
1-phenyl-1,2,3,4-tetrahydroisoquinoline

INVENTOR(S): Perlman, Nurit, Kfar Saba, ISRAEL
Nidam, Tamar, Yehud, ISRAEL

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080091023	A1	20080417
APPLICATION INFO.:	US 2007-890289	A1	20070803 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-835806P	20060803 (60)
	US 2006-845260P	20060918 (60)
	US 2006-845261P	20060918 (60)
	US 2006-859951P	20061120 (60)
	US 2006-859952P	20061120 (60)
	US 2007-878913P	20070104 (60)
	US 2007-898789P	20070131 (60)
	US 2007-898888P	20070131 (60)
	US 2007-930391P	20070515 (60)
	US 2007-949112P	20070711 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: KENYON & KENYON LLP, ONE BROADWAY, NEW YORK, NY, 10004,
US

NUMBER OF CLAIMS: 36

EXEMPLARY CLAIM: 1

LINE COUNT: 413

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Optically pure 1(S)-phenyl-1,2,3,4-tetrahydroisoquinoline tartrate is prepared. The 1(S)-phenyl-1,2,3,4-tetrahydroisoquinoline tartrate is particularly useful for preparing solifenacin succinate.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 242478-37-1P, Solifenacin
(solifenacin base forms and preparation thereof)

RN 242478-37-1 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 8 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2008:98565 USPATFULL
TITLE: METHODS FOR TREATING LOWER URINARY TRACT DISORDERS
USING ALPHA2DELTA SUBUNIT CALCIUM CHANNEL MODULATORS
WITH SMOOTH MUSCLE MODULATORS
INVENTOR(S): Fraser, Matthew Oliver, Apex, NC, UNITED STATES
Thor, Karl Bruce, Morrisville, NC, UNITED STATES
Burgard, Edward C., Chapel Hill, NC, UNITED STATES
Brettman, Lee R., Sudbury, MA, UNITED STATES
Landau, Steven B., Wellesley, MA, UNITED STATES
Ricca, Daniel J., Rougemont, NC, UNITED STATES
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., Boston, MA, UNITED
STATES, 02116 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080085916	A1	20080410
APPLICATION INFO.:	US 2007-952422	A1	20071207 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-805977, filed on 22 Mar 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-456835P	20030321 (60)
	US 2003-486148P	20030710 (60)
	US 2003-509570P	20031008 (60)
	US 2004-534871P	20040108 (60)
	US 2004-548250P	20040227 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000, US	
NUMBER OF CLAIMS:	54	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	23 Drawing Page(s)	
LINE COUNT:	4701	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is provided for using α .sub.2 δ subunit calcium channel modulators or other compounds that interact with the α .sub.2 δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, α .sub.2 δ subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β 3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 242478-37-1, Solifenacin
(methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators)
RN 242478-37-1 USPATFULL
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 9 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2008:80749 USPATFULL
TITLE: SPECIFIC GLUCOCORTICOSTEROID COMPOUND HAVING
ANTI-INFLAMMATORY ACTIVITY
INVENTOR(S): BIGGADIKE, KEITH, Stevenage, UNITED KINGDOM
NEEDHAM, Deborah, Stevenage, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080070880	A1	20080320
APPLICATION INFO.:	US 2007-863390	A1	20070928 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2006-564325, filed on 17 May 2006, GRANTED, Pat. No. US 7288536 A 371 of International Ser. No. WO 2004-EP7819, filed on 9 Jul 2004		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2003-16290	20030711
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US	
NUMBER OF CLAIMS:	25	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1524	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of formula (I): ##STR1## wherein X represents O or S;
R.sub.1 represents C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8
cycloalkylmethyl or C.sub.3-8 cycloalkenyl any of which optionally may
be substituted by one or more methyl groups or halogen atoms or R.sub.1
represents aryl, substituted aryl, heteroaryl or substituted heteroaryl;
R.sub.2 represents hydrogen, methyl, which may be in either the α or
 β configuration, or methylene;
R.sub.3 and R.sub.4 are the same or different and each independently represents
hydrogen, halogen or a methyl group;
and ##custom-character-00001## represents a single or a double bond; or a
physiologically acceptable salt or solvate thereof, and pharmaceutical
formulations and methods of use thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2008:44893 USPATFULL

TITLE: Composition of Solifenacin or Salt Thereof for Use in Solid Formulation

INVENTOR(S): Sugihara, Akio, Yaizu-shi, JAPAN
Yasuji, Takehiko, Yaizu-shi, JAPAN
Masaki, Katsuhiko, Yaizu-shi, JAPAN
Murayama, Daisuke, Yaizu-shi, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080039516	A1	20080214
APPLICATION INFO.:	US 2005-594127	A1	20050324 (10)
	WO 2005-JP5377		20050324
			20060925 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-556025P	20040325 (60)
	US 2004-638388P	20041227 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SUGHRUE-265550, 2100 PENNSYLVANIA AVE. NW, WASHINGTON, DC, 20037-3213, US	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1063	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A solid pharmaceutical preparation of solifenacin or a salt thereof, the preparation being stable and inhibited from decomposing with time when supplied to clinical fields. In a pharmaceutical preparation containing solifenacin or a salt thereof, the compound in an amorphous form was revealed to be causative of cardinal-drug decomposition with time. The composition for a solid pharmaceutical preparation of solifenacin or a salt thereof contains solifenacin or its salt each in a crystalline form, and the content provided are: a process for producing the composition; and a medicinal composition for solid pharmaceutical preparations which contains solifenacin and an amorphization inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 242478-37-1, Solifenacin


(solid pharmaceutical compns. containing crystalline solifenacin having improved

stability, and manufacture thereof)

RN 242478-37-1 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 11 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2008:44821 USPATFULL

TITLE: COMPOUNDS

INVENTOR(S): GORE, Paul Martin, Stevenage, UNITED KINGDOM
HANCOCK, Ashley Paul, Stevenage, UNITED KINGDOM
HODGSON, Simon Teanby, Stevenage, UNITED KINGDOM
KINDON, Leanda Jane, Stevenage, UNITED KINGDOM

PATENT ASSIGNEE(S): GLAXO GROUP LIMITED, Greenford, UNITED KINGDOM, UB6 0NN
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080039444	A1	20080214
APPLICATION INFO.:	US 2007-736602	A1	20070418 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2006-7839	20060420
	GB 2007-6160	20070329
	GB 2007-6176	20070329

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI
B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE
PARK, NC, 27709-3398, US

NUMBER OF CLAIMS: 12

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 3 Drawing Page(s)

LINE COUNT: 4527

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to compounds of formula (I), ##STR1##
and salts thereof, processes for their preparation, to compositions
containing them and to their use in the treatment of various disorders,
such as allergic rhinitis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 12 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2008:24050 USPATFULL

TITLE: Novel compounds

INVENTOR(S): BIGGADIKE, KEITH, Stevenage, UNITED KINGDOM
NEEDHAM, Deborah, Stevenage, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080021231	A1	20080124
APPLICATION INFO.:	US 2007-863419	A1	20070928 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2006-564325, filed on 17 May 2006, GRANTED, Pat. No. US 7288536 A 371 of International Ser. No. WO 2004-EP7819, filed on 9 Jul 2004		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2003-16290	20030711
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US	

NUMBER OF CLAIMS: 18

EXEMPLARY CLAIM: 1

LINE COUNT: 1547

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of formula (I): ##STR1## wherein X represents O or S;

R.sub.1 represents C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkylmethyl or C.sub.3-8 cycloalkenyl any of which optionally may be substituted by one or more methyl groups or halogen atoms or R.sub.1 represents aryl, substituted aryl, heteroaryl or substituted heteroaryl;

R.sub.2 represents hydrogen, methyl, which may be in either the α or β configuration, or methylene;

R.sub.3 and R.sub.4 are the same or different and each independently represents hydrogen, halogen or a methyl group;

and ##custom-character-00001## represents a single or a double bond; or a physiologically acceptable salt or solvate thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 13 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2008:17703 USPATFULL
TITLE: Novel compounds
INVENTOR(S): JOHN, MATTHEW PETER, Stevenage, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080015360	A1	20080117
APPLICATION INFO.:	US 2007-863439	A1	20070928 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2006-564325, filed on 17 May 2006, GRANTED, Pat. No. US 7288536 A 371 of International Ser. No. WO 2004-EP7819, filed on 9 Jul 2004		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2003-16290	20030711
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US	
NUMBER OF CLAIMS:	1	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1454	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of formula (I): ##STR1## wherein X represents O or S;

R.sub.1 represents C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkylmethyl or C.sub.3-.sub.8 cycloalkenyl any of which optionally may be substituted by one or more methyl groups or halogen atoms or R.sub.1 represents aryl, substituted aryl, heteroaryl or substituted heteroaryl;

R.sub.2 represents hydrogen, methyl, which may be in either the α or β configuration, or methylene;

R.sub.3 and R.sub.4 are the same or different and each independently represents hydrogen, halogen or a methyl group;

and ##custom-character-00001## represents a single or a double bond; or a physiologically acceptable salt or solvate thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 14 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2008:11114 USPATFULL

TITLE: Methods and compositions for the treatment of urinary incontinence

INVENTOR(S): Skolnick, Phil, Edgewater, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080009538	A1	20080110
APPLICATION INFO.:	US 2006-384219	A1	20060317 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-664002P	20050321 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BLACK LOWE & GRAHAM PLLC, Suite 4800, 701 Fifth Avenue, Seattle, WA, 98104, US	
NUMBER OF CLAIMS:	39	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	1622	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions containing bicifadine are provided for the prevention and treatment of lower urinary tract disorders in mammalian subjects. The methods and compositions may be used to prevent or treat urinary incontinence, urinary urgency, nocturia, and enuresis associated with neurogenic and non-neurogenic overactive bladder, interstitial cystitis, prostatitis, prostatic hyperplasia, and benign prostatic hyperplasia, among other conditions. Additional compositions and methods are provided which employ bicifadine in combination with a second anti-incontinence agent, or a different therapeutic agent to yield more effective anti-incontinence treatment tools, and/or dual activity therapeutic methods and formulations useful to prevent or reduce urinary incontinence and one or more additional symptoms such as urinary urgency, overflow, frequency, or pain in mammalian subjects.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 242478-37-1, Solifenacin
(methods and compns. containing bicifadine for treatment of urinary incontinence)

RN 242478-37-1 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 15 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2008:5069 USPATFULL
TITLE: Combinations of Statins with Bronchodilators
INVENTOR(S): Lindmark, Bertil, Lund, SWEDEN
Thoren, Anders Ingemar, Lund, SWEDEN
PATENT ASSIGNEE(S): ASTRAZENECA AB, Sodertalje, SWEDEN (non-U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080004247	A1	20080103
APPLICATION INFO.:	US 2005-571869	A1	20050620 (11)
	WO 2005-GB2413		20050620
			20070109 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2004-15789	20040715
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & RICHARDSON P.C., P.O BOX 1022, MINNEAPOLIS, MN, 55440-1022, US	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	504	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides medicaments comprising combinations of
bronchodilators, glucocorticosteroids and HMG-CoA reductase inhibitors
in the treatment of respiratory disorders such as chronic obstructive
pulmonary disease (COPD).


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 242478-37-1, Solifenacin
(combinations of statins with bronchodilators for treatment of
respiratory disorders)

RN 242478-37-1 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 16 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2007:327903 USPATFULL
TITLE: Personal audio listening device
INVENTOR(S): Liu, Chun-Hsin, Taipei Hsien, TAIWAN, PROVINCE OF CHINA
Wu, Chung-Chun, Taipei, TAIWAN, PROVINCE OF CHINA
Hung, Yu-Chang, Taipei Hsien, TAIWAN, PROVINCE OF CHINA
Liu, Liang-Yi, Taipei, TAIWAN, PROVINCE OF CHINA
PATENT ASSIGNEE(S): Lite-On Technology Corporation (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070286409	A1	20071213
APPLICATION INFO.:	US 2006-593079	A1	20061106 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	TW 2006-95210095	20060609
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ROSENBERG, KLEIN & LEE, 3458 ELLICOTT CENTER DRIVE-SUITE 101, ELLICOTT CITY, MD, 21043, US	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	799	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A personal audio listening device is adapted to be worn on a user's ear, and includes a housing, a pivotal knob, and an ear hook member. The housing has a surface and a hollow portion, and defines a first axis and a second axis. The pivotal knob is pivotally mounted on the surface of the housing, and includes a pair of parallel resilient walls. The ear hook member includes a hook body and an end portion. The end portion includes a pivot element in the form of a polygonal post. The hook body is configured to be wearable on the user's ear. The ear hook member is fittingly received between the resilient walls by means of the pivot element so as to be mounted on the pivotal knob. The ear hook member is pivotable about the first axis, and is rotatable about the second axis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 242478-37-1P, Solifenacin
(process for preparing solifenacin with small amount of derivative thereof)
RN 242478-37-1 USPATFULL
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 17 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2007:303329 USPATFULL

TITLE: NOVEL COMPOUNDS

INVENTOR(S): BIGGADIKE, Keith, Stevenage, UNITED KINGDOM
COOPER, Anthony William James, Stevenage, UNITED KINGDOM

HOUSE, David, Stevenage, UNITED KINGDOM

MCLAY, Iain McFarlane, Stevenage, UNITED KINGDOM

Woollam, Grhame Robert, Stevenage, UNITED KINGDOM

PATENT ASSIGNEE(S): GLAXO GROUP LIMITED, Greenford, UNITED KINGDOM, UB6 0NN
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070265326	A1	20071115
APPLICATION INFO.:	US 2007-736606	A1	20070418 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2006-7840	20060420
	GB 2006-20382	20061013
	GB 2007-6515	20070403
	GB 2007-6516	20070403

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI
B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE
PARK, NC, 27709-3398, US

NUMBER OF CLAIMS: 9

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 2 Drawing Page(s)

LINE COUNT: 2956

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compounds of formula (I): ##STR1##
pharmaceutical compositions comprising the compounds and the use of the
compounds for the manufacture of a medicament, particularly for the
treatment of inflammation and/or allergic conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 18 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2007:296135 USPATFULL

TITLE: Chimeric and Humanised Monoclonal Antibodies Against Interleukin-13

INVENTOR(S): Ashman, Claire, King of Prussia, PA, UNITED STATES
Cassidy, Martin John, Hertfordshire, UNITED KINGDOM
Ellis, Jonathan Henry, Hertfordshire, UNITED KINGDOM
Wattam, Trevor Anthony Kenneth, Hertfordshire, UNITED KINGDOM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20070258979	A1	20071108	
APPLICATION INFO.:	US 2005-570736	A1	20050630	(11)
	WO 2005-GB2581		20050630	
			20061215	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2004-14799	20040701
	GB 2004-23675	20041025
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SMITHKLINE BEECHAM CORPORATION, CORPORATE INTELLECTUAL PROPERTY-US, UW2220, P. O. BOX 1539, KING OF PRUSSIA, PA, 19406-0939, US	
NUMBER OF CLAIMS:	63	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	29 Drawing Page(s)	
LINE COUNT:	4996	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention concerns immunoglobulins, particularly antibodies which specifically bind human Interleukin 13 (hIL-13). Antibodies of the invention may be used in the treatment of a variety of diseases or disorders responsive to modulation of the interaction between hIL-13 and the human IL-13 receptor. Such diseases include severe asthma, atopic dermatitis, COPD and various fibrotic diseases. Pharmaceutical compositions comprising said antibodies and methods of manufacture are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 19 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2007:285116 USPATFULL

TITLE: IL-8 Receptor Antagonists

INVENTOR(S): BUSCH-PETERSEN, Jakob, King of Prussia, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070249672	A1	20071025
APPLICATION INFO.:	US 2007-738148	A1	20070420 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2006-793881P	20060421 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SMITHKLINE BEECHAM CORPORATION, CORPORATE INTELLECTUAL PROPERTY-US, UW2220, P. O. BOX 1539, KING OF PRUSSIA, PA, 19406-0939, US	

NUMBER OF CLAIMS: 5

EXEMPLARY CLAIM: 1

LINE COUNT: 1761

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to novel compounds and compositions thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 20 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2007:285048 USPATFULL

TITLE: 3-Monosubstituted tropane derivatives as nociceptin receptor ligands

INVENTOR(S): Ho, Ginny D., Murray Hill, NJ, UNITED STATES

Tulshian, Deen, Lebanon, NJ, UNITED STATES

Yang, Shu-Wei, Edison, NJ, UNITED STATES

PATENT ASSIGNEE(S): Schering Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070249604	A1	20071025
APPLICATION INFO.:	US 2006-589388	A1	20061030 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-731703P	20051031 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530, US	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1595	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein

R.sup.1 is aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl or alkyl, all optionally substituted;

R.sup.2 is H; or aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl or alkyl, all optionally substituted;

R.sup.3 is aryl, heteroaryl, cycloalkyl or heterocycloalkyl, all optionally substituted;

X is a bond, --(CH.sub.2).sub.m--N(R.sup.7)--(CH.sub.2).sub.n--, --(CH.sub.2).sub.m--O--(CH.sub.2).sub.n--, --(CH.sub.2).sub.m--S--CH.sub.2).sub.n--, --C(O)--, --CH(OH)--, --C(O)N(R.sup.7)--, --C(O)N(R.sup.7)-alkylene or --N(R.sup.7)C(O)--;

R.sup.7 is H or alkyl; and m and n are each 0-6, provided that the sum of m and n is 0-6; or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions thereof, and the use of said compounds in the treatment of cough, pain, anxiety, asthma, depression, alcohol abuse, urinary incontinence and overactive bladder are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 242478-37-1, Solifenacin

(combination chemotherapy co-drug; monosubstituted tropane derivs. as nociceptin receptor ligands)

RN 242478-37-1 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 21 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2007:256190 USPATFULL

TITLE: Tetrahydro-Naphthalene Derivatives as Glucocorticoid Receptor Modulators

INVENTOR(S): Edwards, Christine, Essex, UNITED KINGDOM

Fenton, Garry, Essex, UNITED KINGDOM

MacDonald, Simon John Fawcett, Hertfordshire, UNITED KINGDOM

Weingarten, Gordon Gad, Hertfordshire, UNITED KINGDOM

Gladwin, Amanda Rachel, Middlesex, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070224130	A1	20070927
APPLICATION INFO.:	US 2005-573301	A1	20050810 (11)
	WO 2005-EP8763		20050810
			20070206 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2004-18045	20040812
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US	
NUMBER OF CLAIMS:	45	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2008	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to compounds of formula (I):

##STR1## wherein R represents a methyl or an ethyl group

X represents N, C--H or C--CH.sub.3

when X represents C--H or C--CH.sub.3, Y represents N when X represents N, Y represents C--H and physiologically functional derivatives thereof, pharmaceutical compositions comprising the compounds, the use of the compounds for the manufacture of medicaments particularly for the treatment of inflammatory and/or allergic conditions, processes for the preparation of the compounds, and chemical intermediates in the processes for the manufacture of the compounds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 22 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2007:218465 USPATFULL
TITLE: Solifenacin-containing composition
INVENTOR(S): Inakoshi, Masatoshi, Chuo-Ku, JAPAN
Ishii, Yusuke, Chuo-Ku, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070191425	A1	20070816
APPLICATION INFO.:	US 2005-593079	A1	20050311 (10)
	WO 2005-JP4342		20050311
			20060915 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2004-133123	20040428
	US 2004-553123P	20040316 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800, WASHINGTON, DC, 20037, US	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	458	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB To provide a novel method for producing a composition comprising solifenacin or a salt thereof, and a composition comprising solifenacin or a salt thereof as produced by the method, wherein an optionally substituted lower alkyl is added to the 2-position of the quinuclidine of solifenacin. The composition of the present invention contains a highly pure solifenacin, while the unexpected compounds specific to the method in an extremely low content, so that it has very preferable properties as a bulk for pharmaceutical products.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 242478-37-1P, Solifenacin
(process for preparing solifenacin with small amount of derivative thereof)
RN 242478-37-1 USPATFULL
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 23 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2007:211521 USPATFULL
TITLE: Method for producing solifenacin or salts thereof
INVENTOR(S): Inakoshi, Masatoshi, Chuo-ku, JAPAN
Ishii, Yusuke, Chuo-ku, JAPAN
PATENT ASSIGNEE(S): ASTELLAS PHARMA INC. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070185329	A1	20070809
APPLICATION INFO.:	US 2005-587826	A1	20050425 (11)
	WO 2005-JP7771		20050425
			20061027 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2004-133283	20040428
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SUGHRUE MION, PLLC, 2100 PENNSYLVANIA AVENUE, N.W., SUITE 800, WASHINGTON, DC, 20037, US	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	999	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB There is provided a novel method for producing solifenacin or a salt thereof which is useful as a medicine, particularly a therapeutic agent and/or a preventive agent for a urinary organ system disease such as pollakiuria or urinary incontinence. Illustratively, there are provided (1) a method for producing solifenacin in which 2-(1H-imidazolylcarbonyl)-1-phenyltetrahydroisoquinoline is used as the starting material, (2) a method for producing solifenacin succinate in which (1RS)-phenyltetrahydroisoquinoline-carboxylic acid quinuclidinyl ester is used as the starting material, (3) a method for producing solifenacin in which a lower alkyl quinuclidinyl carbonate is used as the starting material and (4) a method for producing solifenacin in which phenyltetrahydroisoquinoline-carboxylic acid secondary lower alkyl or tertiary lower alkyl ester is used as the starting material and allowed to react with an alkali metal lower alkoxide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 242478-37-1P, Solifenacin
(process for preparing solifenacin with small amount of derivative thereof)
RN 242478-37-1 USPATFULL
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 24 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2007:198180 USPATFULL
TITLE: Process for preparing solifenacin
INVENTOR(S): Perlman, Nurit, Kfar Saba, ISRAEL
Nidam, Tamar, Yehud, ISRAEL

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070173528	A1	20070726
APPLICATION INFO.:	US 2006-645021	A1	20061221 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-753236P	20051221 (60)
	US 2006-835802P	20060803 (60)
	US 2006-860642P	20061122 (60)
	US 2006-873022P	20061206 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KENYON & KENYON LLP, ONE BROADWAY, NEW YORK, NY, 10004,
US
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 465

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided are new intermediates of solifenacin and methods for their preparation, as well as methods of preparing solifenacin and solifenacin succinate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 242478-37-1P, Solifenacin

(preparation of solifenacin)

RN 242478-37-1 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 25 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2007:178017 USPATFULL
TITLE: New Method for Treating Urinary Disorders
INVENTOR(S): Danehower, Susan M., New York, NY, UNITED STATES
Korberly, Barbara Helene, Flemington, NJ, UNITED STATES
PATENT ASSIGNEE(S): Pfizer Inc (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070155838	A1	20070705
APPLICATION INFO.:	US 2007-677071	A1	20070221 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-762726, filed on 22 Jan 2004, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-441690P	20030122 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340, US	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
LINE COUNT:	460	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method, preferable an oral method, for treating urinary disorders, such as unstable or overactive bladder, while minimizing the occurrences of dry mouth, dyspeptia and reduced stream of tears. The methods of the present invention comprise orally administering to a mammal, preferably a human, a pharmaceutically effective dose of an antimuscarinic agent, such as tolterodine, when needed, whereby a symptomatic relief of urgency and/or frequency is achieved.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 242478-37-1, Solifenacin
(tolterodine or other antimuscarinic agent dose reduction for treatment of urinary disorders)

RN 242478-37-1 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 26 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2007:170792 USPATFULL

TITLE: Nanoparticulate inclusion and charge complex for pharmaceutical formulations

INVENTOR(S): Fischer, Katrin Claudia, Berlin, GERMANY, FEDERAL REPUBLIC OF
General, Sascha, Berlin, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070149479	A1	20070628
APPLICATION INFO.:	US 2006-514323	A1	20060901 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2005-10200504186020050902	
	US 2005-713332P	20050902 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201, US	
NUMBER OF CLAIMS:	39	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	931	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A Nanoparticulate inclusion and charge complex that comprises at least two complex partners, whereby a complex partner is an anionic inclusion-forming agent and another complex partner is a cationic active ingredient.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 242478-37-1, Solifenacin
(nanoparticulate inclusion and charge complex for pharmaceutical formulations)

RN 242478-37-1 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 27 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2007:148291 USPATFULL
TITLE: Spirocyclic Derivatives
INVENTOR(S): Rawson, David J., Sandwich, UNITED KINGDOM
Swain, Nigel A., Sandwich, UNITED KINGDOM
PATENT ASSIGNEE(S): Pfizer, Inc. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070129388	A1	20070607
APPLICATION INFO.:	US 2006-565953	A1	20061201 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-741854P	20051202 (60)
	US 2006-791186P	20060410 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WARNER-LAMBERT COMPANY, 2800 PLYMOUTH RD, ANN ARBOR, MI, 48105, US	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	2889	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides compounds of formula (I): ##STR1## wherein: m is 0, 1 or 2; X is O, S or N--CN; R is F, Cl or CN;
A is a C.sub.3-6 cycloalkylene group optionally substituted with a C.sub.1-4 alkyl group; and
B is a single bond or a C.sub.1-2 alkylene group; or a pharmaceutically acceptable salt, solvate, polymorph or prodrug thereof. The compounds are PDE7 inhibitors and have a number of therapeutic applications, particularly in the treatment of pain, especially neuropathic pain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 242478-37-1, Solifenacin
(phosphodiesterase 7 inhibiting compds. useful in treatment of neuropathic pain)
RN 242478-37-1 USPATFULL
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 28 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2007:69397 USPATFULL

TITLE: Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators

INVENTOR(S): Fraser, Matthew Oliver, Apex, NC, UNITED STATES
Thor, Karl Bruce, Morrisville, NC, UNITED STATES
Burgard, Edward C., Chapel Hill, NC, UNITED STATES
Brettman, Lee R., Sudbury, MA, UNITED STATES
Landau, Steven B., Wellesley, MA, UNITED STATES

PATENT ASSIGNEE(S): Ricca, Daniel J., Rougemont, NC, UNITED STATES
Dynogen Pharmaceuticals, Inc., Waltham, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070060652	A1	20070315
APPLICATION INFO.:	US 2006-598393	A1	20061113 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2003-400666, filed on 28 Mar 2003, GRANTED, Pat. No. US 7043248		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000, US		
NUMBER OF CLAIMS:	5		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	23 Drawing Page(s)		
LINE COUNT:	4525		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is provided for using α .sub.2 δ subunit calcium channel modulators or other compounds that interact with the α .sub.2 δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, α .sub.2 δ subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β 3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 242478-37-1, Solifenacin
(methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators)

RN 242478-37-1 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 29 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2007:61861 USPATFULL
TITLE: THERAPY FOR THE TREATMENT OF DISEASE
INVENTOR(S): Paborji, Mehdi, 10351 Byrne Avenue, Cupertino, CA,
UNITED STATES 95014
PATENT ASSIGNEE(S): THERAVIDA, LLC, Irvine, CA, UNITED STATES (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070053995	A1	20070308
APPLICATION INFO.:	US 2006-467760	A1	20060828 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-714150P	20050902 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Vista IP Law Group LLP, 2040 MAIN STREET, 9TH FLOOR, IRVINE, CA, 92614, US	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	1436	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein are pharmaceutical compositions comprising various combinations of an antimuscarinic or an anticholinergic agent, a compound that causes stimulation of salivary glands, and a compound that relieves constipation. Also disclosed are methods of treating a patient suffering from overactive bladder comprising administering to the patient the above pharmaceutical composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 242478-37-1, Solifenacin
(therapy for treatment of disease)
RN 242478-37-1 USPATFULL
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 30 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2007:49181 USPATFULL

TITLE: Specific glucocorticosteroid compounds having
anti-inflammatory activity

INVENTOR(S): Biggadike, Keith, Stevenage, UNITED KINGDOM
Needham, Deborah, Stevenage, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070043007	A1	20070222
	US 7291609	B2	20071106
APPLICATION INFO.:	US 2004-564299	A1	20040709 (10)
	WO 2004-EP7820		20040709
			20060912 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2003-16290	20030711
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US	

NUMBER OF CLAIMS: 8

EXEMPLARY CLAIM: 1

LINE COUNT: 716

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of formula (I): ##STR1## or a physiologically acceptable
solvate thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 31 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2006:341515 USPATFULL

TITLE: Compounds

INVENTOR(S): Bamford, Mark James, Harlow, UNITED KINGDOM
Dean, David Kenneth, Harlow, UNITED KINGDOM
Hancock, Ashley Paul, Stevenage, UNITED KINGDOM
Wilson, David Matthew, Harlow, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060293298	A1	20061228
APPLICATION INFO.:	US 2005-246480	A1	20051007 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2005-551985, filed on 4 Oct 2005, PENDING A 371 of International Ser. No. WO 2004-EP3985, filed on 8 Apr 2004		

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2003-8333	20030410
	GB 2005-10731	20050525
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1002	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to 1-([4-(1-Azetidinylcarbonyl)phenyl]carbonyl)-4-(4-([1-(1-methylethyl)-4-piperidinyl]oxy)phenyl)piperidine ##STR1## and derivatives thereof, and to compositions, processes for its preparation and its uses in therapy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 32 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2006:322496 USPATFULL

TITLE: Methods for treating functional bowel disorders using
alpha2 subunit calcium channel modulators with smooth
muscle modulators

INVENTOR(S): Fraser, Matthew Oliver, Apex, NC, UNITED STATES
Thor, Karl Bruce, Morrisville, NC, UNITED STATES
Burgard, Edward C., Chapel Hill, NC, UNITED STATES
Brettman, Lee R., Sudbury, MA, UNITED STATES
Landau, Steven B., Wellesley, MA, UNITED STATES
Ricca, Daniel J., Rougermont, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060276542	A1	20061207
APPLICATION INFO.:	US 2004-549998	A1	20040322 (10)
	WO 2004-US8701		20040322
			20060623 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-486148P	20030710 (60)
	US 2003-509570P	20031008 (60)
	US 2004-534871P	20040108 (60)
	US 2004-548250P	20040227 (60)
	US 2004-551551P	20040309 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH
TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000, US

NUMBER OF CLAIMS: 36

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 4 Drawing Page(s)

LINE COUNT: 3849

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is provided for using α .sub.2 δ subunit calcium
channel modulators or other compounds that interact with the
 α .sub.2 δ calcium channel subunit in combination with one or,
more compounds with smooth muscle modulatory effects to treat functional
bowel disorders in patients in need of treatment. According to the
present invention, α .sub.2 δ subunit calcium channel
modulators include GABA analogs including gabapentin and pregabalin,
fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino
acid compounds. Compounds with smooth muscle modulatory effects include
antimuscarinics, β 3 adrenergic agonists, spasmolytics, neurokinin
receptor antagonists, bradykinin receptor antagonists, and nitric oxide
donors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 242478-37-1, Solifenacin

(methods for treating lower urinary tract disorders using smooth muscle
modulators and alpha-2-delta subunit calcium channel modulators)

RN 242478-37-1 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 33 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2006:308896 USPATFULL

TITLE: Methods for treating pain using smooth muscle modulators and $\alpha 2$ subunit calcium channel modulators

INVENTOR(S): Fraser, Matthew Oliver, Apex, NC, UNITED STATES
Thor, Karl Bruce, Morrisville, NC, UNITED STATES
Burgard, Edward C, Chapel Hill, NC, UNITED STATES
Brettman, Lee R., Sudbury, MA, UNITED STATES
Landau, Steven B., Wellesley, MA, UNITED STATES
Ricca, Daniel J., Rougemont, NC, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20060264509	A1	20061123	
APPLICATION INFO.:	US 2004-549829	A1	20040322	(10)
	WO 2004-US8700		20040322	
			20060623	PCT 371 date

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-456835P	20030321	(60)
	US 2003-486148P	20030710	(60)
	US 2003-509570P	20031008	(60)
	US 2004-534871P	20040108	(60)
	US 2004-548250P	20040227	(60)
	US 2004-551671P	20040309	(60)
	US 2004-551551P	20040309	(60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000, US

NUMBER OF CLAIMS: 38

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 4 Drawing Page(s)

LINE COUNT: 4230

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is provided for using α .sub.2 δ subunit calcium channel modulators or other compounds that interact with the α .sub.2 δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat pain. According to the present invention, α .sub.2 δ subunit calcium channel modulators include GABA analogs (e.g., gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, $\beta 3$ adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 242478-37-1, Solifenacin

(methods for treating lower urinary tract disorders using smooth muscle modulators and α -2- δ subunit calcium channel modulators)

RN 242478-37-1 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 34 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2006:289316 USPATFULL

TITLE: Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators

INVENTOR(S): Fraser, Matthew Oliver, Apex, NC, UNITED STATES
Thor, Karl Bruce, Morrisville, NC, UNITED STATES
Burgard, Edward C., Chapel Hill, NC, UNITED STATES
Brettman, Lee R., Sudbury, MA, UNITED STATES
Landau, Steven B., Wellesley, MA, UNITED STATES

PATENT ASSIGNEE(S): Ricca, Daniel J., Rougemont, NC, UNITED STATES
Dynogen Pharmaceuticals, Inc., Waltham, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060247311	A1	20061102
APPLICATION INFO.:	US 2006-400666	A1	20060407 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-805977, filed on 22 Mar 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-456835P	20030321 (60)
	US 2003-486148P	20030710 (60)
	US 2003-509570P	20031008 (60)
	US 2004-534871P	20040108 (60)
	US 2004-548250P	20040227 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000, US

NUMBER OF CLAIMS: 6

EXEMPLARY CLAIM: 1-43

NUMBER OF DRAWINGS: 23 Drawing Page(s)

LINE COUNT: 4600

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is provided for using α .sub.2 δ subunit calcium channel modulators or other compounds that interact with the α .sub.2 δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, α .sub.2 δ subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β 3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 242478-37-1, Solifenacin

(methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators)

RN 242478-37-1 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 35 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2006:289225 USPATFULL

TITLE: Specific glucocorticosteriod compound having anti-inflammatory activity

INVENTOR(S): Biggadike, Keith, Hertfordshire, UNITED KINGDOM
John, Peter Matthew, Hertfordshire, UNITED KINGDOM
Needham, Deborah, Hertfordshire, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060247219	A1	20061102
	US 7288536	B2	20071030
APPLICATION INFO.:	US 2004-564325	A1	20040709 (10)
	WO 2004-EP7819		20040709
			20060517 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2003-16290	20030711
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US	

NUMBER OF CLAIMS: 22

EXEMPLARY CLAIM: 1

LINE COUNT: 1625

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A compound of formula (I): (I) wherein X represents O or S; R1 represents C1-6 alkyl, C3-8 cycloalkyl, C3-8 cycloalkylmethyl or C3-8 cycloalkenyl any of which optionally may be substituted by one or more methyl groups or halogen atoms or R1 represents aryl, substituted aryl, heteroaryl or substituted heteroaryl; R2 represents hydrogen, methyl, which may be in either the α or β configuration, or methylene; R3 and R4 are the same or different and each independently represents hydrogen, halogen or a methyl group; and represents a single or a double bond; or a physiologically acceptable salt or solvate thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 36 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2006:199069 USPATFULL

TITLE: Combination of selected opioids with other active substances for use in the therapy of urinary incontinence

INVENTOR(S): Nakagawa, Shinji, Tokyo, JAPAN
Hori, Toshio, Tokyo, JAPAN
Nemoto, Mamoru, Tokyo, JAPAN
Nagano, Masami, Tokyo, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006168942	A1	20060803
	US 7246486	B2	20070724
APPLICATION INFO.:	US 2003-545901	A1	20030430 (10)
	WO 2003-EP5529		20030430
			20050817 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-10224107	20020529
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CROWELL & MORING LLP, INTELLECTUAL PROPERTY GROUP, P.O. BOX 14300, WASHINGTON, DC, 20044-4300, US	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	36 Drawing Page(s)	
LINE COUNT:	1166	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An internal combustion engine control device for, in a lean-burn internal combustion engine provided with a three-way catalyst and a lean NOx catalyst in an exhaust system, optimizing an air/fuel ratio in a rich mode from the viewpoints of both better fuel economy and exhaust emission control when NOx having been stored in a lean NOx catalyst during a lean operation is desorbed and cleaned by switching to a rich operation.

An internal combustion engine control device for controlling an air/fuel ratio during the rich operation to be changed between a period of desorbing O.sub.2 stored in the three-way catalyst and a period of desorbing and cleaning NOx stored in the lean NOx catalyst.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 242478-37-1, Solifenacin
(opioid combination with other active substances for treatment of urinary incontinence)

RN 242478-37-1 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 37 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2006:189447 USPATFULL

TITLE: Medicinal composition

INVENTOR(S): Yamagata, Tsuyoshi, Shizuoka, JAPAN
Shirakura, Shiro, Shizuoka, JAPAN

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Chiyoda-ku, JAPAN,
100-8185 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006160887	A1	20060720
APPLICATION INFO.:	US 2004-562635	A1	20040716 (10)
	WO 2004-JP10521		20040716
			20051229 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2003-197662	20030716
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FITZPATRICK CELLA HARPER & SCINTO, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112, US	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	712	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a pharmaceutical composition which is useful in the treatment for overactive bladder and the like, and comprises 3,3,3-trifluoro-2-hydroxy-2-methyl-N-(5,5,10-trioxo-4,10-dihydrothieno[3,2-c][1]benzothiepin-9-yl)propanamide or a pharmaceutically acceptable salt thereof, and an anticholinergic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 242478-37-1, Solifenacin

(medicinal compns. containing tricyclic heterocyclic compound and anticholinergic agent)

RN 242478-37-1 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 38 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2006:54702 USPATFULL

TITLE: Method for treating urinary disorders

INVENTOR(S): Danehower, Susan M., New York, NY, UNITED STATES

Korberly, Barbara Helene, Flemington, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060047007	A1	20060302
APPLICATION INFO.:	US 2004-762726	A1	20040122 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-441690P	20030122 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PFIZER INC., PATENT DEPARTMENT, MS8260-1611, EASTERN POINT ROAD, GROTON, CT, 06340, US	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
LINE COUNT:	455	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a method, preferable an oral method, for treating urinary disorders, such as unstable or overactive bladder, while minimizing the occurrences of dry mouth, dyspepsia and reduced stream of tears. The methods of the present invention comprise orally administering to a mammal, preferably a human, a pharmaceutically effective dose of an antimuscarinic agent, such as tolterodine, when needed, whereby a symptomatic relief of urgency and/or frequency is achieved.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 242478-37-1, Solifenacin

(tolterodine or other antimuscarinic agent dose reduction for treatment of urinary disorders)

RN 242478-37-1 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 39 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2006:22130 USPATFULL

TITLE: Compounds

INVENTOR(S): Ancliff, Ranchael Ann, Stevenage, UNITED KINGDOM
Eldred, Colin David, Stevenage, UNITED KINGDOM
Fogden, Yvonne C., Stevenage, UNITED KINGDOM
Hancock, Ashley Paul, Stevenage, UNITED KINGDOM
Heightman, Thomas Daniel, Harlow, UNITED KINGDOM
Hobbs, Heather, Stevenage, UNITED KINGDOM
Hodgson, Simon Teanby, Stevenage, UNITED KINGDOM
Lindon, Matthew J., Stevenage, UNITED KINGDOM
Wilson, David Matthew, Harlow, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060019964	A1	20060126
APPLICATION INFO.:	US 2005-112048	A1	20050422 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2002-24084	20021016
	GB 2005-3846	20050224
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GLAXOSMITHKLINE, CORPORATE INTELLECTUAL PROPERTY, MAI B475, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398, US	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
LINE COUNT:	947	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	1-{4-[(1-Cyclobutyl-4-piperidinyl)oxy]phenyl}-4-{[4- (methylsulfonyl)phenyl]carbonyl}piperazine	##STR1## or a derivative thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 40 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2005:330235 USPATFULL

TITLE: Oral pharmaceutical compositions in timed-release particle form and fast-disintegrating tablets containing this composition

INVENTOR(S): Yoshida, Takayuki, Tokyo, JAPAN

Tasaki, Hiroaki, Tokyo, JAPAN

Katsuma, Masataka, Tokyo, JAPAN

Maeda, Atsushi, Tokyo, JAPAN

PATENT ASSIGNEE(S): Astellas Pharma Inc., Tokyo, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050287211	A1	20051229
APPLICATION INFO.:	US 2005-119460	A1	20050428 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-567301P	20040430 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834, US	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	3402	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to an oral pharmaceutical composition in particle form, which comprises particles that contain a drug at the core of the pharmaceutical composition in particle form; a middle layer that contains two types of water-soluble components, an insolubilizer and an insolubilizing substance; and an outer layer for controlling water penetration that contains a water-insoluble substance. The present invention makes it possible to provide a pharmaceutical composition in particle form for oral use with which initial drug release is suppressed, the drug is quickly released thereafter, and lag time can be controlled as needed, and fast-disintegrating tablets containing this composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 242478-37-1, Solifenacin

(multilayer coated cores for controlled-release granules and tablets containing the granules)

RN 242478-37-1 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 41 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2005:275325 USPATFULL
TITLE: Methods for decreasing detrusor muscle overactivity
INVENTOR(S): Fraser, Matthew Oliver, Apex, NC, UNITED STATES
Thor, Karl Bruce, Morrisville, NC, UNITED STATES
Burgard, Edward C., Chapel Hill, NC, UNITED STATES
Brettman, Lee R., Sudbury, MA, UNITED STATES
Landau, Steven B., Wellesley, MA, UNITED STATES
Ricca, Daniel J., Rougemont, NC, UNITED STATES
PATENT ASSIGNEE(S): Dynogen Pharmaceuticals, Inc., Boston, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050239890	A1	20051027
APPLICATION INFO.:	US 2005-126062	A1	20050510 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-805977, filed on 22 Mar 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-456835P	20030321 (60)
	US 2003-486148P	20030710 (60)
	US 2003-509570P	20031008 (60)
	US 2004-534871P	20040108 (60)
	US 2004-548250P	20040227 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000, US	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1-19	
NUMBER OF DRAWINGS:	23 Drawing Page(s)	
LINE COUNT:	4620	


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is provided for using α .sub.28 subunit calcium channel modulators or other compounds that interact with the α .sub.28 calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, α .sub.28 subunit calcium channel modulators include GABA analogs, e.g., gabapentin and pregabalin, fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β 3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 242478-37-1, Solifenacin
(methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators)
RN 242478-37-1 USPATFULL
CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 42 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2005:208553 USPATFULL

TITLE: Solifenacin transdermal preparation and method for enhancing transdermal permeation thereof

INVENTOR(S): Saito, Katsumi, Yaizu-shi, JAPAN
Katsuma, Masataka, Yaizu-shi, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050181031	A1	20050818
APPLICATION INFO.:	US 2005-61858	A1	20050218 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-545623P	20040218 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KILYK & BOWERSOX, P.L.L.C., 53 A EAST LEE STREET, WARRENTON, VA, 20186, US	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	628	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The transdermal permeable property of solifenacin or a salt thereof as a biologically active substance, is remarkably improved using a fatty acid ester, a terpene or the like as a selected transdermal permeable promoter. The difference in effect exceeded expectations by producing an enhancement in permeability that represents an increase of several hundredfold at most, and several tenfold for practical application, enabling the provision of extremely useful means for preventive and therapeutic agents for urologic diseases or respiratory diseases that use solifenacin.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 242478-37-1, Solifenacin
(solifenacin transdermal preparation comprising permeation enhancers)

RN 242478-37-1 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 43 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2005:158984 USPATFULL

TITLE: Combination of selected opioids with other active compounds for treatment of urinary incontinence

INVENTOR(S): Cristoph, Thomas, Aachen, GERMANY, FEDERAL REPUBLIC OF

PATENT ASSIGNEE(S): Gruenenthal GmbH, Aachen, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050137194	A1	20050623
APPLICATION INFO.:	US 2004-998164	A1	20041129 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2003-EP5529, filed on 27 May 2003, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 2002-10224107	20020529
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CROWELL & MORING LLP, INTELLECTUAL PROPERTY GROUP, P.O. BOX 14300, WASHINGTON, DC, 20044-4300, US	
NUMBER OF CLAIMS:	55	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2107	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the combination of compounds of group A, especially opioids, with compounds of group B for the treatment of urinary urgency or urinary incontinence. The invention also relates to corresponding pharmaceutical formulations and to methods for treating urinary urgency or urinary incontinence with a compound of group A and a compound of group B.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 242478-37-1, Solifenacin
(opioid combination with other active substances for treatment of urinary incontinence)

RN 242478-37-1 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 44 OF 45 USPATFULL on STN

ACCESSION NUMBER: 2004:255292 USPATFULL

TITLE: Methods for treating lower urinary tract disorders using alpha2delta subunit calcium channel modulators with smooth muscle modulators

INVENTOR(S): Fraser, Matthew Oliver, Apex, NC, UNITED STATES
Thor, Karl Bruce, Morrisville, NC, UNITED STATES
Burgard, Edward C., Chapel Hill, NC, UNITED STATES
Brettman, Lee R., Sudbury, MA, UNITED STATES
Landau, Steven B., Wellesley, MA, UNITED STATES

PATENT ASSIGNEE(S): Ricca, Daniel J., Rougemont, NC, UNITED STATES
Dynogen Pharmacueticals, Inc., Boston, MA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040198822	A1	20041007
APPLICATION INFO.:	US 2004-805977	A1	20040322 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-456835P	20030321 (60)
	US 2003-486148P	20030710 (60)
	US 2003-509570P	20031008 (60)
	US 2004-534871P	20040108 (60)
	US 2004-548250P	20040227 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: ALSTON & BIRD LLP, BANK OF AMERICA PLAZA, 101 SOUTH TRYON STREET, SUITE 4000, CHARLOTTE, NC, 28280-4000

NUMBER OF CLAIMS: 43

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 23 Drawing Page(s)

LINE COUNT: 4835

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method is provided for using α .sub.2 δ subunit calcium channel modulators or other compounds that interact with the α .sub.2 δ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, α .sub.2 δ subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β 3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 242478-37-1, Solifenacin

(methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators)

RN 242478-37-1 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-, (3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L4 ANSWER 45 OF 45 USPATFULL on STN
ACCESSION NUMBER: 2004:179083 USPATFULL
TITLE: Quaternary ammonium compounds
INVENTOR(S): Slatter, John Gregory, Bellevue, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040138253	A1	20040715
APPLICATION INFO.:	US 2003-688442	A1	20031017 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-421951P	20021029 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PHARMACIA & UPJOHN, 301 HENRIETTA ST, 0228-32-LAW, KALAMAZOO, MI, 49007	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
LINE COUNT:	388	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention features quaternary ammonium compounds of formula I,
described herein, and their use in treating asthma, chronic obstructive
pulmonary disorder, allergic rhinitis, and infectious rhinitis.


CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 242478-37-1D, quaternary ammonium salts
(preparation of quaternary ammonium quinuclidinium derivs. as antimuscarinic
agents for the treatment of asthma, chronic obstructive pulmonary
disease, and allergic and infectious rhinitis)

RN 242478-37-1 USPATFULL

CN 2(1H)-Isoquinolinecarboxylic acid, 3,4-dihydro-1-phenyl-,
(3R)-1-azabicyclo[2.2.2]oct-3-yl ester, (1S)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

221.47

236.78

STN INTERNATIONAL LOGOFF AT 07:57:42 ON 26 JUN 2008